| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-09-19 | Biomay (Austria) | €5 million | private placement and loan | existing shareholders | Allergic diseases - Immunological diseases | Private placement |
| 2013-09-18 | EpimiRNA Consortium | €11.5 million | grant | European Commission’s Seventh Framework Program (FP7) | CNS diseases | Grant |
| 2013-09-18 | Protalix BioTherapeutics (Israel) | $66.8 million | private placement | Rare diseases - Autoimmune diseases - Genetic diseases | Private placement | |
| 2013-09-18 | Morphosys (Germany) | € 84 million | private placement | Cancer - Oncology | Private placement | |
| 2013-09-16 | Therametrics, formerly known as Mondobiotech (Switzerland) | private placement | Private placement | |||
| 2013-09-16 | BioVersys (Switzerland) -University of Applied Sciences (ZHAW) (Switzerland), the University of Applied Science North Western Switzerland (FHNW) (Switzerland), Muttenz, and research groups of the Universities of Basel, Berne and Geneva (Switzerland) | CHF 2.1 million | grant | Commission for Technology and Innovation (CTI) (Switzerland) | Infectious diseases | Grant |
| 2013-09-13 | Karo Bio (Sweden) | $0,5 million (€0.376 million) | grant | National Multiple Sclerosis Society | Neurodegenerative diseases | Grant |
| 2013-09-11 | Skuldtech (France) | € 1 million | grant and repayable advances | bpifrance (France) | Diagnostic - Neurodegenerative diseases | Grant |
| 2013-09-11 | Oxford Biomedica (UK) | £7.1 million (€ 8.4 million) | award and loan | Government’s Advanced Manufacturing Supply Chain Initiative (AMSCI) (UK) | Loan | |
| 2013-09-09 | DuecomplusA (UK), subsidiary of drug delivery specialists Moreinx (Sweden) | € 1 million | crowdfunding | Cancer - Oncology | Fundraising | |
| 2013-09-06 | Canbex Therapeutics (UK) | £1.25 million (€ 1.48 million) | grant | Biomedical Catalyst Fund (UK) | Neurodegenerative diseases | Grant |
| 2013-09-05 | Piqur Therapeutics (Switzerland) | grant and seed financing round | European Eurostars Programme (EU) | Cancer - Oncology | Grant | |
| 2013-09-04 | Mind-NRG (Switzerland) | € 6 million | series B financing round | Index Ventures (Switzerland) LRM (Belgium) |
CNS diseases - Neurodegenerative diseases | Series B financing round |
| 2013-09-03 | Leukocare (Germany) | € 3.4 million | private placement | Private placement | ||
| 2013-09-03 | Volition Rx (Singapore) | €779,493 | grant | European Eurostars Programme (EU) | Cancer - Oncology | Grant |
| 2013-09-03 | Acacia Pharma (UK) | £15 million (€17.7 million) | series B financing round | Fidelity Biosciences (USA), Novo A/S (Denmark), Gilde Healthcare (The Netherlands), Lundbeckfond Ventures (Denmark) | Series B financing round | |
| 2013-09-03 | Arsanis (USA - MA) | $20 million | series B financing round | NeoMed Management (Switzerland) OrbiMed Advisors (USA -NY), Polaris Venture Partners (USA - MA) SV Life Sciences (USA - MA) | Infectious diseases | Series B financing round |
| 2013-08-31 | Evotec (Germany) | € 30 million | private placement | Biotechnology Value Fund (USA), BVF Partners L.P. (USA) | Private placement | |
| 2013-08-29 | ObsEva (Switzerland) | CHF 32 million (€25.6 million) | series A financing round | Sofinnova Partners (France) Sofinnova Ventures (USA) Novo A/S (Denamrk) | Gynecology - Women's health | Series A financing round |
| 2013-08-27 | Desktop Genetics (UK) | £375,000 (€436,218) | equity investment | Boundary Capital Ltd (UK), Execute Technologies (UK), Richard Youngman, Michael Martin (both of Anvil Partners LLP) (UK), Dr Jonathan Milner (CEO, AbCam Plc) (UK), Dr Darrin M Disley (CEO, Horizon Discovery Ltd) (UK) | Fundraising |
